Quick Answer
Cytosorbents Corp reported Research And Development Expense of $15.73 million for the year ending 2023.
- Cytosorbents Corp showed an increase of +4.0% in Research And Development Expense from 2022 to 2023.
- This data is from Cytosorbents Corp's annual report (Form 10-K), filed with the SEC on March 15, 2024.
- XBRL data for this metric is available from 2010 to 2023 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: $704.1 thousand | Q2 2013: $708.2 thousand | Q3 2013: $294.2 thousand | Q1 2014: $236.8 thousand | Q2 2014: $347.0 thousand | Q3 2014: $880.3 thousand | Q1 2015: $951.0 thousand | Q2 2015: $801.7 thousand | Q3 2015: $866.3 thousand | Q1 2016: $856.1 thousand | Q2 2016: $1.09 million | Q3 2016: $1.17 million | Q1 2017: $469.5 thousand | Q2 2017: $458.0 thousand | Q3 2017: $643.2 thousand | Q1 2018: $1.73 million | Q2 2018: $1.58 million | Q3 2018: $1.94 million | Q1 2019: $2.42 million | Q2 2019: $2.93 million | Q3 2019: $3.19 million | Q1 2020: $1.97 million | Q2 2020: $2.41 million | Q3 2020: $1.75 million | Q1 2021: $2.28 million | Q2 2021: $3.70 million | Q3 2021: $4.26 million | Q1 2022: $4.24 million | Q2 2022: $4.18 million | Q3 2022: $3.29 million | Q1 2023: $4.21 million | Q2 2023: $3.67 million | Q3 2023: $3.75 million | Q1 2024: $2.25 million | Q2 2024: $1.52 million | Q3 2024: $1.85 million.
- Over the full 14 years of available data (2010 to 2023), Cytosorbents Corp's Research And Development Expense has grown by 795.0%.
- Historical annual values: Fiscal year 2023: $15.73 million | Fiscal year 2022: $15.12 million | Fiscal year 2021: $16.38 million | Fiscal year 2020: $8.81 million | Fiscal year 2019: $12.09 million | Fiscal year 2018: $7.72 million | Fiscal year 2017: $3.22 million | Fiscal year 2016: $4.07 million | Fiscal year 2015: $3.87 million | Fiscal year 2014: $2.43 million | Fiscal year 2013: $1.74 million | Fiscal year 2012: $2.53 million | Fiscal year 2011: $2.89 million | Fiscal year 2010: $1.76 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: